Targets of T cell responses to #SARS-CoV-2 #coronavirus in humans with #COVID-19 disease and unexposed individuals : Cell
►https://www.cell.com/cell/abstract/S0092-8674(20)30610-3
Étude de la réponse immunitaire dans les COVID-19 ne nécessitant pas une hospitalisation et recherche d’une immunité croisée chez les sujets (a priori ?) non exposés au sars-cov2.
Analysé ci-dessous par un des auteurs
Thread by profshanecrotty : Our new paper rapidly studied T cell + antibody immune responses in average COVID-19 cases. This is good news in multiple ways, including co…
▻https://threadreaderapp.com/thread/1261052353773363200.html
https://threadreaderapp.com/images/screenshots/thread/1261052353773363200.jpg 
https://pbs.twimg.com/media/EYAoJxBUEAAbKKu?format=jpg&name=large#.jpg In our study, 100% of COVID-19 cases made antibodies. 100% of COVID-19 cases made CD4 T cells. 70% of COVID-19 cases made measurable CD8 T cells. We believe these findings are good news, and consistent with normal antiviral immunity.
CD4+ T cell responses to spike, the main target of most vaccine efforts, were robust and correlated with the magnitude of the anti-SARS-CoV-2 IgG and IgA titers. Again, good news.
We specifically chose to study people who had an average COVID19 disease course—non-hospitalized —to provide a solid benchmark for what a normal immune response to SARS2 looks like.
Additionally, any potential for crossreactive immunity from other coronaviruses has been predicted by epidemiologists to have significant implications for the pandemic going forwards. We detected SARS-CoV-2-reactive CD4+ T cells in ~50% of unexposed individuals .
Detecting SARS2-reactive T cells in ~50% of unexposed people suggests cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS-CoV-2. This might influence susceptibility to COVID-19 disease.
Crossreactive T cells are also relevant for vaccine development, as cross-reactive immunity could influence responsiveness to candidate vaccines.
Whether this immunity is relevant in influencing clinical outcomes is unknown, but it is tempting to speculate that the crossreactive CD4+ T cells may be of value in protective immunity, based on SARS and flu data.
